Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by Algert Global LLC

Algert Global LLC lifted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 10.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,700 shares of the company’s stock after acquiring an additional 1,505 shares during the period. Algert Global LLC’s holdings in Keros Therapeutics were worth $717,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Keros Therapeutics by 1.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock worth $870,000 after purchasing an additional 251 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after buying an additional 324 shares during the last quarter. Principal Financial Group Inc. increased its position in Keros Therapeutics by 8.8% in the 1st quarter. Principal Financial Group Inc. now owns 7,063 shares of the company’s stock valued at $468,000 after acquiring an additional 574 shares during the period. Arizona State Retirement System increased its position in Keros Therapeutics by 16.3% in the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after acquiring an additional 1,130 shares during the period. Finally, American International Group Inc. raised its stake in Keros Therapeutics by 13.1% during the 1st quarter. American International Group Inc. now owns 12,653 shares of the company’s stock valued at $838,000 after acquiring an additional 1,465 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Trading Up 1.7 %

KROS stock opened at $60.90 on Friday. Keros Therapeutics, Inc. has a 52 week low of $27.02 and a 52 week high of $73.00. The company has a market cap of $2.20 billion, a P/E ratio of -11.83 and a beta of 1.23. The company’s 50-day moving average price is $51.11 and its 200 day moving average price is $52.45.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same quarter in the prior year, the company posted ($1.27) EPS. On average, equities research analysts expect that Keros Therapeutics, Inc. will post -4.88 earnings per share for the current year.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now owns 119,522 shares of the company’s stock, valued at $5,260,163.22. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 22.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Guggenheim assumed coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price objective for the company. Bank of America lowered their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, September 12th. Oppenheimer assumed coverage on shares of Keros Therapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price target for the company. Finally, Truist Financial restated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $90.63.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.